Bio‑Rad posts Q3 2026 results with strong profit and modest revenue outlook
+4 new sources since this summary was written
Bio‑Rad Laboratories reported third‑quarter 2026 net sales of $656.4 million and GAAP net income of $458.6 million, delivering earnings per share of $17.02. Adjusted earnings were $2.65 per share and the non‑GAAP operating margin expanded to 12.8%. The company reaffirmed its full‑year 2026 outlook, expecting non‑GAAP, currency‑neutral revenue to range from a 3.0% decline to a 0.5% increase and an operating margin of 10.0%‑12.0%.
Why it matters
The profit result and adjusted EPS show the business generated solid cash flow despite flat revenue, which may support the current share price. The modest full‑year revenue range and margin guidance signal limited growth upside, influencing investors’ expectations for the remainder of 2026.
Key facts
- 1Q3 2026 net sales were $656.4 million. stocktitan.net
- 2GAAP net income for the quarter was $458.6 million. stocktitan.net
- 3GAAP earnings per diluted share were $17.02. finance.yahoo.com
- 4Adjusted (non‑GAAP) earnings per diluted share were $2.65. stocktitan.net
- 5Non‑GAAP operating margin was 12.8%. stocktitan.net
- 6Full‑year 2026 non‑GAAP, currency‑neutral revenue is expected to be between a 3.0% decline and a 0.5% increase. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.